Comparing ProMetic Life Sciences (OTCMKTS:PFSCF) & Vaxxinity (NASDAQ:VAXX)

Profitability

This table compares ProMetic Life Sciences and Vaxxinity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
Vaxxinity	N/A	N/A	N/A

Risk and Volatility

ProMetic Life Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -2.09, meaning that its stock price is 309% less volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares ProMetic Life Sciences and Vaxxinity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
Vaxxinity	N/A	N/A	-$56.93 million	($0.45)	-0.05

Vaxxinity has lower revenue, but higher earnings than ProMetic Life Sciences.

Summary

Vaxxinity beats ProMetic Life Sciences on 6 of the 8 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.